<div class="headers"><div>Figure 2. Change in glycosylated hemoglobin (HbA1c) from baseline to 24 weeks in patients with type 2 diabetes treated with insulin lispro protamine suspension 75%/insulin lispro solution 25% (LM25) or basal insulin glargine once daily plus prandial insulin lispro once daily (IGL), grouped according to main meal (the meal with the highest 2 hour postprandial blood glucose level, as determined from three separate 7 point self-monitoring of blood glucose profiles); all changes significant versus baseline (p < 0.0001). Data are presented as box plots, which allow presentation of multiple statistical endpoints (diamonds ¼ mean; horizontal lines ¼ median; end margins of boxes ¼25th and 75th percentile values).</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; text-align: left;'><p style="" class="">Figure 2. Change in glycosylated hemoglobin (HbA1c) from baseline to 24 weeks in patients with type 2 diabetes treated with insulin lispro protamine suspension 75%/insulin lispro solution 25% (LM25) or basal insulin glargine once daily plus prandial insulin lispro once daily (IGL), grouped according to main meal (the meal with the highest 2 hour postprandial blood glucose level, as determined from three separate 7 point self-monitoring of blood glucose profiles); all changes significant versus baseline (p < 0.0001). </p></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="" class="">Data are presented as box plots, which allow presentation of multiple statistical endpoints (diamonds ¼ mean; horizontal lines ¼ median; end margins of boxes ¼25th and 75th percentile values).</p></td>
</tr>
</tbody>
</table>
